Endo International plc (ENDP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
21.49+0.68 (+3.27%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close20.81
Bid20.10 x 100
Ask24.94 x 500
Day's Range20.80 - 21.87
52wk Range12.56 - 68.84
1y Target EstN/A
Market Cap4.79B
P/E Ratio (ttm)-4.92
Avg Vol (3m)6,317,546
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Barrons.com2 days ago

    Valeant Pharmaceuticals: Stay Far Away, JPMorgan Says

    In a report looking ahead to earnings from specialty pharmaceutical companies like Allergan (AGN), and Endo International (ENDP), JPMorgan's Chris Schott and team call Valeant Pharmaceuticals International (VRX) a name to "avoid." They explain why: Ahead of 3Q EPS results, we wanted to share our latest thoughts on our Specialty Pharma group. For names we would own into 3Q, we would highlight Allergan, Endo International and Akorn (AKRX) and would avoid Valeant and Impax Laboratories (IPXL), where we see risk to guidance given the implied steep 2H ramp... Valeant: Remain cautious into a widely expected guidance cut.

  • PR Newswire5 days ago

    Endo Announces Departure of Chief Financial Officer

    DUBLIN, Oct. 20, 2016 /PRNewswire/ -- Endo International plc (ENDP) (ENL.TO) announced today that Suketu Upadhyay, Executive Vice President and Chief Financial Officer, is leaving the Company effective November 22, 2016 to assume a senior-level finance position at a global biopharmaceutical company. Blaise Coleman, Endo's Senior Vice President of Global Finance Operations, will serve as Interim Chief Financial Officer. The Company will promptly begin a search for a permanent Chief Financial Officer.

  • CNW Group5 days ago

    Endo Announces Departure of Chief Financial Officer

    Endo Announces Departure of Chief Financial Officer